Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-1: Phase 3 study of weekly eloralintide in adults with obesity or overweight without type 2 diabetes
CTR20261716Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eloralintide in obesity, Overweight, sponsored by Eli Lilly and Company. Started May 2026; status: active.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20261716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261716.